MA29775B1 - Derives de pyrazolone - Google Patents
Derives de pyrazoloneInfo
- Publication number
- MA29775B1 MA29775B1 MA30744A MA30744A MA29775B1 MA 29775 B1 MA29775 B1 MA 29775B1 MA 30744 A MA30744 A MA 30744A MA 30744 A MA30744 A MA 30744A MA 29775 B1 MA29775 B1 MA 29775B1
- Authority
- MA
- Morocco
- Prior art keywords
- pyrazolone derivatives
- pyrazolone
- esters
- formula
- pharmaceutically acceptable
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/18—One oxygen or sulfur atom
- C07D231/20—One oxygen atom attached in position 3 or 5
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/18—One oxygen or sulfur atom
- C07D231/20—One oxygen atom attached in position 3 or 5
- C07D231/22—One oxygen atom attached in position 3 or 5 with aryl radicals attached to ring nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/18—One oxygen or sulfur atom
- C07D231/20—One oxygen atom attached in position 3 or 5
- C07D231/22—One oxygen atom attached in position 3 or 5 with aryl radicals attached to ring nitrogen atoms
- C07D231/26—1-Phenyl-3-methyl-5- pyrazolones, unsubstituted or substituted on the phenyl ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
- C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Child & Adolescent Psychology (AREA)
- Ophthalmology & Optometry (AREA)
- Endocrinology (AREA)
- Vascular Medicine (AREA)
- Emergency Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Dérivés de pyrazolone Des composés de formule (I) ainsi que leurs sels et esters pharmaceutiquement acceptables, formule dans laquelle R1 à R4 répondent aux définitions indiquées dans la revendication 1, peuvent être utilisés sous forme de compositions pharmaceutiques.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP05107970 | 2005-08-31 |
Publications (1)
Publication Number | Publication Date |
---|---|
MA29775B1 true MA29775B1 (fr) | 2008-09-01 |
Family
ID=37729936
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA30744A MA29775B1 (fr) | 2005-08-31 | 2008-03-14 | Derives de pyrazolone |
Country Status (23)
Country | Link |
---|---|
US (1) | US7652057B2 (fr) |
EP (1) | EP1924562A2 (fr) |
JP (1) | JP5073664B2 (fr) |
KR (1) | KR100982088B1 (fr) |
CN (1) | CN101243050B (fr) |
AR (1) | AR055145A1 (fr) |
AU (1) | AU2006286646B2 (fr) |
BR (1) | BRPI0615039A2 (fr) |
CA (1) | CA2618840C (fr) |
CR (1) | CR9703A (fr) |
EC (1) | ECSP088229A (fr) |
HK (1) | HK1123295A1 (fr) |
IL (1) | IL189186A0 (fr) |
MA (1) | MA29775B1 (fr) |
MX (1) | MX2008002583A (fr) |
MY (1) | MY145464A (fr) |
NO (1) | NO20080554L (fr) |
NZ (1) | NZ565536A (fr) |
RU (1) | RU2407737C2 (fr) |
TW (1) | TWI332949B (fr) |
UA (1) | UA90742C2 (fr) |
WO (1) | WO2007025880A2 (fr) |
ZA (1) | ZA200801444B (fr) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9145424B2 (en) | 2008-11-20 | 2015-09-29 | Northwestern University | Treatment of amyotrophic lateral sclerosis |
US9428467B2 (en) | 2008-11-20 | 2016-08-30 | Northwestern University | Selective calcium channel antagonists |
WO2010059241A2 (fr) | 2008-11-20 | 2010-05-27 | Cambria Pharmaceuticals, Inc. | Traitement de la sclérose latérale amyotrophique |
ES2535490T3 (es) * | 2009-05-22 | 2015-05-12 | Abbvie Inc. | Preparación de moduladores de receptores 5-HT |
WO2011051958A1 (fr) | 2009-10-30 | 2011-05-05 | E.I. Du Pont De Nemours And Company | Pyrazolones fongicides |
CN104860951A (zh) * | 2010-05-21 | 2015-08-26 | Abbvie公司 | 5-ht受体的调节剂和其使用方法 |
EP2881387A1 (fr) | 2013-12-09 | 2015-06-10 | Basf Se | Composés pyrazolone à activité herbicide |
EP2881388A1 (fr) | 2013-12-09 | 2015-06-10 | Basf Se | Composés pyrazolone à activité herbicide |
EP3235813A1 (fr) | 2016-04-19 | 2017-10-25 | Cidqo 2012, S.L. | Dérivés aza-tétra-cycliques |
WO2019048988A1 (fr) | 2017-09-08 | 2019-03-14 | Pi Industries Ltd. | Nouveaux composés hétérocycliques fongicides |
EP3679035A1 (fr) | 2017-09-08 | 2020-07-15 | PI Industries Ltd. | Nouveaux composés hétérocycliques fongicides |
WO2020210922A1 (fr) * | 2019-04-17 | 2020-10-22 | Pontificia Universidad Católica De Chile | DÉRIVÉS D'ADAMANTYLOXADIAZOLES ET LEURS SOLVATES, HYDRATES ET SELS PHARMACEUTIQUEMENT ACCEPTABLES, COMPOSITION PHARMACEUTIQUE LES COMPRENANT, PROCÉDÉ DE SYNTHÈSE, UTILES EN TANT QU'INHIBITEURS EFFICACES ET SÉLECTIFS DE L'ACTIVITÉ RÉDUCTASE DE L'ENZYME 11-BÊTA DÉSHYDROGÉNASE DE TYPE 1 (11β-HSD1) |
CN113527207B (zh) * | 2020-04-22 | 2023-06-06 | 常州强力电子新材料股份有限公司 | 乙氧基/丙氧基改性的吡唑啉有机物、其应用、光固化组合物及光刻胶 |
CN112375072B (zh) * | 2020-09-28 | 2021-05-28 | 上海长征富民金山制药有限公司 | 吡唑啉酮衍生物、注射剂及其用途 |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2731473A (en) * | 1956-01-17 | New pyrazolone derivatives | ||
DE668628C (de) * | 1935-12-08 | 1938-12-07 | Beiersdorf & Co A G P | Verfahren zur Darstellung von Alkyl- und Aralkylabkoemmlingen der 3,4-Cyclotetramethylen-1-aryl-5-pyrazolone |
JPS609752B2 (ja) * | 1979-11-09 | 1985-03-12 | 東邦新薬株式会社 | 新規な2−アセトキシベンズアミド誘導体、その製法及びそれを有効成分とする医薬 |
DE4415484A1 (de) | 1994-05-03 | 1995-11-09 | Basf Ag | Verfahren zur Herstellung von 1-(Het)aryl-3-hydroxy-pyrazolen |
US5663365A (en) * | 1996-10-29 | 1997-09-02 | Japan Hydrazine Co., Ltd. | Process for the preparation of pyrazolones |
DK0870757T3 (da) * | 1997-04-10 | 2002-07-15 | Pfizer | Fluorsubstituerede adamantanderivater |
TW536387B (en) * | 1998-04-23 | 2003-06-11 | Sumitomo Chemical Co | Pyrazolinone compound |
TR200201082T2 (tr) * | 1999-08-31 | 2002-07-22 | Kissei Pharmaceutical Co., Ltd. | Glikopriranoziloksipirazol türevleri |
DK1354888T3 (da) * | 2000-12-28 | 2009-09-21 | Kissei Pharmaceutical | Glukopyranosyloxypyrazolderivater og anvendelse deraf i medikamenter |
EP1541564A1 (fr) * | 2002-09-10 | 2005-06-15 | Takeda Pharmaceutical Company Limited | Composes heterocycliques a cinq elements |
WO2004056324A2 (fr) | 2002-12-19 | 2004-07-08 | Bristol-Myers Squibb Company | Gamma-carbolines tricycliques substituees utilisees comme agonistes et antagonistes du recepteur de la serotonine |
GB0306718D0 (en) * | 2003-03-24 | 2003-04-30 | Sterix Ltd | Compound |
CA2534221A1 (fr) | 2003-08-07 | 2005-02-24 | Merck & Co., Inc. | Carboxamides de pyrazole utilises comme inhibiteurs de la dehydrogenase-1 11-beta-hydroxysteroide |
-
2006
- 2006-08-21 MX MX2008002583A patent/MX2008002583A/es active IP Right Grant
- 2006-08-21 EP EP06792909A patent/EP1924562A2/fr not_active Withdrawn
- 2006-08-21 UA UAA200803780A patent/UA90742C2/ru unknown
- 2006-08-21 CA CA2618840A patent/CA2618840C/fr not_active Expired - Fee Related
- 2006-08-21 KR KR1020087004807A patent/KR100982088B1/ko not_active IP Right Cessation
- 2006-08-21 CN CN2006800305234A patent/CN101243050B/zh not_active Expired - Fee Related
- 2006-08-21 JP JP2008528461A patent/JP5073664B2/ja not_active Expired - Fee Related
- 2006-08-21 NZ NZ565536A patent/NZ565536A/en not_active IP Right Cessation
- 2006-08-21 AU AU2006286646A patent/AU2006286646B2/en not_active Ceased
- 2006-08-21 MY MYPI20080416A patent/MY145464A/en unknown
- 2006-08-21 RU RU2008111971/04A patent/RU2407737C2/ru not_active IP Right Cessation
- 2006-08-21 WO PCT/EP2006/065471 patent/WO2007025880A2/fr active Application Filing
- 2006-08-21 BR BRPI0615039-0A patent/BRPI0615039A2/pt not_active IP Right Cessation
- 2006-08-29 US US11/511,542 patent/US7652057B2/en not_active Expired - Fee Related
- 2006-08-29 TW TW095131856A patent/TWI332949B/zh not_active IP Right Cessation
- 2006-08-29 AR ARP060103758A patent/AR055145A1/es unknown
-
2008
- 2008-01-29 CR CR9703A patent/CR9703A/es not_active Application Discontinuation
- 2008-01-30 NO NO20080554A patent/NO20080554L/no not_active Application Discontinuation
- 2008-02-03 IL IL189186A patent/IL189186A0/en unknown
- 2008-02-12 ZA ZA200801444A patent/ZA200801444B/xx unknown
- 2008-02-27 EC EC2008008229A patent/ECSP088229A/es unknown
- 2008-03-14 MA MA30744A patent/MA29775B1/fr unknown
-
2009
- 2009-02-03 HK HK09100950.9A patent/HK1123295A1/xx not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
KR20080031482A (ko) | 2008-04-08 |
EP1924562A2 (fr) | 2008-05-28 |
MY145464A (en) | 2012-02-15 |
TW200740764A (en) | 2007-11-01 |
ZA200801444B (en) | 2008-12-31 |
US7652057B2 (en) | 2010-01-26 |
WO2007025880A3 (fr) | 2007-05-03 |
BRPI0615039A2 (pt) | 2011-04-26 |
TWI332949B (en) | 2010-11-11 |
MX2008002583A (es) | 2008-03-18 |
CN101243050B (zh) | 2012-07-04 |
CA2618840A1 (fr) | 2007-03-08 |
NO20080554L (no) | 2008-03-14 |
UA90742C2 (en) | 2010-05-25 |
ECSP088229A (es) | 2008-03-26 |
AU2006286646B2 (en) | 2010-09-23 |
HK1123295A1 (en) | 2009-06-12 |
WO2007025880A2 (fr) | 2007-03-08 |
KR100982088B1 (ko) | 2010-09-13 |
RU2407737C2 (ru) | 2010-12-27 |
JP2009506089A (ja) | 2009-02-12 |
CA2618840C (fr) | 2011-07-05 |
AR055145A1 (es) | 2007-08-08 |
RU2008111971A (ru) | 2009-10-10 |
IL189186A0 (en) | 2008-06-05 |
CR9703A (es) | 2008-02-20 |
JP5073664B2 (ja) | 2012-11-14 |
US20070049574A1 (en) | 2007-03-01 |
AU2006286646A1 (en) | 2007-03-08 |
NZ565536A (en) | 2011-03-31 |
CN101243050A (zh) | 2008-08-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA29775B1 (fr) | Derives de pyrazolone | |
MA29909B1 (fr) | Derives de pyridazine | |
MA30162B1 (fr) | Nouveaux derives de pyrrole a cycles fusionnes | |
MA29856B1 (fr) | Derives de diacylindazole en tant qu'inhibiteurs de lipases et de phospholipases | |
MA27560A1 (fr) | Nouveaux derives de fluorglycoside heterocycliques, produits pharmaceutiques contenant ces composes et leur utilisation | |
HRP20050663A2 (en) | Malonamide derivatives as gamma-secretase inhibitors | |
MA29857B1 (fr) | Derives de triazolopyridine en tant qu'inhibiteurs de lipases et phospholipases | |
MA31580B1 (fr) | Derives de bicyclolactames substitués | |
DE602004008098D1 (de) | Substituierte 2h-ä1,2,4ütriazoloä4,3-aüpyrazine als gsk-3-inhibitoren | |
MA30717B1 (fr) | Derives de pyridin-3-yle en tant qu'agents immunomodulateurs | |
MA30718B1 (fr) | Derives de pyridin-4-yle en tant qu'agents immunomodulateurs. | |
MA27559A1 (fr) | Nouveaux derives de fluorglycoside aromatiques, produits pharmaceutiques contenant ces composes et leur utilisation | |
MA30231B1 (fr) | Derives de benzamides et d'heteroarenes | |
MEP36508A (en) | Triazolopyrazine derivatives useful as anti-cancer agents | |
MA29858B1 (fr) | Derives de carbamoylbenzotriazole en tant qu'inhibiteurs de lipases et phospholipases | |
EA201490489A1 (ru) | Пуриновые производные и их применение в качестве модуляторов толл-подобного рецептора 7 | |
WO2007130075A8 (fr) | Derives aminothiazole utilises en tant qu'inhibiteurs de la stearoyle-coa desaturase humaine | |
MA30352B1 (fr) | Pyridine [3,4-b] pyrazinones | |
MA31683B1 (fr) | Composes et procedes pour moduler fxr | |
MA32563B1 (fr) | Dabigatran pour cathétérisme cardiaque de chirurgie percutanée | |
MA29926B1 (fr) | Derives de pyrazine | |
EP1689713A4 (fr) | Inhibiteurs de benzylether et benzylamino de beta-secretase pour traiter la maladie d'alzheimer | |
MA31296B1 (fr) | Derives d'imidazolidine carboxamide en tant qu'inhibiteurs de lipase et de phospholipase | |
MA47301B1 (fr) | Inhibiteurs sélectifs de jak1 | |
MA37886A1 (fr) | Nouvelles pyridinones bicycliques |